Shopping Cart
Remove All
Your shopping cart is currently empty
T3Inh-1 is a potent and selective ppGalNAc-T3 inhibitor with IC50 of 7 µM. T3Inh-1 protects against breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in tissue cells and mice without causing any toxic side effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $93 | In Stock | In Stock | |
| 5 mg | $228 | In Stock | In Stock | |
| 10 mg | $383 | In Stock | In Stock | |
| 25 mg | $728 | In Stock | In Stock | |
| 50 mg | $1,080 | In Stock | In Stock | |
| 100 mg | $1,480 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $272 | In Stock | In Stock |
| Description | T3Inh-1 is a potent and selective ppGalNAc-T3 inhibitor with IC50 of 7 µM. T3Inh-1 protects against breast cancer cells. T3Inh-1 reduces FGF23 hormone levels in tissue cells and mice without causing any toxic side effects. |
| Targets&IC50 | ppGalNAc-T3:7 µM |
| In vitro | METHODS: Breast cancer MDA-MB231 cells were treated with T3Inh-1 (5μM, 24/48 hours) to observe cell proliferation and cell invasion. RESULTS T3Inh-1 was significantly effective, inhibiting migration by >80% and invasion by 98%, but had no significant effect on cell proliferation. [1] |
| In vivo | METHODS: Mice were injected intraperitoneally with T3Inh-1 and serum cleaved FGF23 levels were measured. Three groups of T3Inh-1 (25 and 50 mg/kg, intraperitoneal injection, 24 hours) were administered and serum cleaved FGF23 levels were measured. RESULTS T3Inh-1 resulted in a robust and statistically significant increase in this ratio at the tested concentrations of 25 and 50 mg/kg, suggesting that T3Inh-1 can mitigate the effects of elevated FGF23 signaling in patients with chronic kidney disease. [1] |
| Molecular Weight | 476.49 |
| Formula | C27H20N6O3 |
| Cas No. | 50440-30-7 |
| Smiles | O=C(NC1=CC=C(C=C1)NC2=CC=NC=C2)C(C=C3)=CC=C3NC4=CC=NC5=C4C=C([N+]([O-])=O)C=C5 |
| Relative Density. | 1.431 g/cm3 (Predicted) |
| Color | Orange |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.77 mg/mL (10.01 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.1 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.